JPRN-jRCT2080220094未知Unknown
A confirmatory study of APTA-2217 in adult patients with bronchial asthma (A placebo-controlled double-blind comparative study)
Mitsubishi Tanabe Pharma was the original trial sponsor; however Astra Zeneca is now the Responsible Party0 个研究点开始时间: 2005年9月12日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 69age old（—）
- 性别
- All
入选标准
- •[Inclusion criteria]
- •Patient with bronchial asthma who are 20 to 70 years old, non-smoker or ex-smoker for 12 months or more, 60 to 80 % of predicted FEV1
- •[Exclusion criteria]
- •Patients with poorly controlled asthma, patients with a clear diagnosis of seasonal asthma and patients who have concurrent respiratory diseases such as COPD, chronic bronchitis, pulmonary emphysema, and bronchiectasis, which are judged to have an effect on the evaluation.
排除标准
- 未提供
研究者
相似试验
未知
Unknown
A confirmatory study of APTA-2217 in patients with chronic obstructive pulmonary disease (A placebo-controlled double-blind, parallel group study)JPRN-jRCT2080220095Mitsubishi Tanabe Pharma was the original trial sponsor; however Astra Zeneca is now the Responsible Party
未知
2 期
Early phase II clinical study with AT-877ER in patients with pulmonary arterial hypertensioPulmonary arterial hypertensionJPRN-jRCT2080220801ASAHI KASEI PHARMA CORPORATIO
进行中（未招募）
1 期
A Phase 2 Study of TAS-117 in Patients with Advanced Solid Tumors Harboring Germline PTEN Inactivating MutationsAdvanced Solid Tumors Harboring Germline PTEN Inactivating MutationsMedDRA version: 23.0Level: PTClassification code 10071986Term: PTEN gene mutationSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-004770-22-ATTaiho Oncology, Inc.100
进行中（未招募）
1 期
A Phase 2 Study of TAS-117 in Patients with Advanced Solid Tumors Harboring Germline PTEN Inactivating MutationsAdvanced Solid Tumors Harboring Germline PTEN Inactivating MutationsMedDRA version: 23.0Level: PTClassification code 10071986Term: PTEN gene mutationSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-004770-22-FRTaiho Oncology, Inc.100
进行中（未招募）
1 期
A Phase 2 Study of TAS-117 in Patients with Advanced Solid Tumors Harboring Germline PTEN Inactivating MutationsAdvanced Solid Tumors Harboring Germline PTEN Inactivating MutationsMedDRA version: 23.0Level: PTClassification code 10071986Term: PTEN gene mutationSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-004770-22-ESTaiho Oncology, Inc.100